| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7630614 | Journal of Pharmaceutical and Biomedical Analysis | 2015 | 40 Pages |
Abstract
- First bioanalytical method has been developed and validated for fidarestat.
- 9.5% of the free form of the drug may be available for the pharmacological action.
- CYP1A2 and CYP2D6 appeared to be the key enzymes for the biotransformation.
- It is a weak inhibitor of CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4.
- It may not alter the pharmacokinetic and clearance of other co-administered drug.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Roshan M. Borkar, Murali Mohan Bhandi, Ajay P. Dubey, Prajwal P. Nandekar, Abhay T. Sangamwar, Sanjay K. Banerjee, R. Srinivas,